The MAGE protein family and cancer

Current Opinion in Cell Biology

Volumn 37, Issue , 2015, Pages 1-8

  Weon, Jenny L ^a   Potts, Patrick Ryan ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN; UBIQUITIN PROTEIN LIGASE; TUMOR ANTIGEN; TUMOR PROTEIN;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; TRANSCRIPTION REGULATION; TUMOR CELL; ANIMAL; DISEASE COURSE; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84940732703     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2015.08.002     Document Type: Review

References (80)

1. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T., Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005, 5:615-625.
2. Mori M., Inoue H., Mimori K., Shibuta K., Baba K., Nakashima H., Haraguchi M., Tsuji K., Ueo H., Barnard G.F., et al. Expression of MAGE genes in human colorectal carcinoma. Ann Surg 1996, 224:183-188.
3. Brasseur F., Rimoldi D., Lienard D., Lethe B., Carrel S., Arienti F., Suter L., Vanwijck R., Bourlond A., Humblet Y., et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995, 63:375-380.
4. Barrow C., Browning J., MacGregor D., Davis I.D., Sturrock S., Jungbluth A.A., Cebon J. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006, 12:764-771.
5. Scarcella D.L., Chow C.W., Gonzales M.F., Economou C., Brasseur F., Ashley D.M. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 1999, 5:335-341.
6. Tajima K., Obata Y., Tamaki H., Yoshida M., Chen Y.T., Scanlan M.J., Old L.J., Kuwano H., Takahashi T., Takahashi T., et al. Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer 2003, 42:23-33.
7. Gure A.O., Chua R., Williamson B., Gonen M., Ferrera C.A., Gnjatic S., Ritter G., Simpson A.J., Chen Y.T., Old L.J., et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005, 11:8055-8062.
8. Kim Y.D., Park H.R., Song M.H., Shin D.H., Lee C.H., Lee M.K., Lee S.Y. Pattern of cancer/testis antigen expression in lung cancer patients. Int J Mol Med 2012, 29:656-662.
9. Karpf A.R., Bai S., James S.R., Mohler J.L., Wilson E.M. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 2009, 7:523-535.
10. Otte M., Zafrakas M., Riethdorf L., Pichlmeier U., Loning T., Janicke F., Pantel K. MAGE-A gene expression pattern in primary breast cancer. Cancer Res 2001, 61:6682-6687.
11. Ayyoub M., Scarlata C.M., Hamai A., Pignon P., Valmori D. Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival. J Immunother 2014, 37:73-76.
12. Barker P.A., Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 2002, 67:705-712.
13. Doyle J.M., Gao J., Wang J., Yang M., Potts P.R. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell 2010, 39:963-974.
14. Hao Y.H., Doyle J.M., Ramanathan S., Gomez T.S., Jia D., Xu M., Chen Z.J., Billadeau D.D., Rosen M.K., Potts P.R. Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination. Cell 2013, 152:1051-1064.
15. Pineda C.T., Ramanathan S., Fon Tacer K., Weon J.L., Potts M.B., Ou Y.H., White M.A., Potts P.R. Degradation of AMPK by a cancer-specific ubiquitin ligase. Cell 2015, 160:715-728.
16. Zhang S., Zhai X., Wang G., Feng J., Zhu H., Xu L., Mao G., Huang J. High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival. Int J Clin Exp Pathol 2015, 8:541-550.
17. Yang F., Zhou X., Miao X., Zhang T., Hang X., Tie R., Liu N., Tian F., Wang F., Yuan J. MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis. Breast Cancer Res Treat 2014, 145:23-32.
18. Daudi S., Eng K.H., Mhawech-Fauceglia P., Morrison C., Miliotto A., Beck A., Matsuzaki J., Tsuji T., Groman A., Gnjatic S., et al. Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One 2014, 9:e104099.
19. Xu Y., Wang C., Zhang Y., Jia L., Huang J. Overexpression of MAGE-A9 is predictive of poor prognosis in epithelial ovarian cancer. Sci Rep 2015, 5:12104.
20. Jeon C.H., Kim I.H., Chae H.D. Prognostic value of genetic detection using CEA and MAGE in peritoneal washes with gastric carcinoma after curative resection: result of a 3-year follow-up. Medicine (Baltimore) 2014, 93:e83.
21. Gu X., Fu M., Ge Z., Zhan F., Ding Y., Ni H., Zhang W., Zhu Y., Tang X., Xiong L., et al. High expression of MAGE-A9 correlates with unfavorable survival in hepatocellular carcinoma. Sci Rep 2014, 4:6625.
22. Yang B., O'Herrin S., Wu J., Reagan-Shaw S., Ma Y., Nihal M., Longley B.J. Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol 2007, 127:267-275.
23. Atanackovic D., Hildebrandt Y., Jadczak A., Cao Y., Luetkens T., Meyer S., Kobold S., Bartels K., Pabst C., Lajmi N., et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 2010, 95:785-793.
24. Yang B., O'Herrin S.M., Wu J., Reagan-Shaw S., Ma Y., Bhat K.M., Gravekamp C., Setaluri V., Peters N., Hoffmann F.M., et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 2007, 67:9954-9962.
25. Liu W., Cheng S., Asa S.L., Ezzat S. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 2008, 68:8104-8112.
26. Bhatia N., Xiao T.Z., Rosenthal K.A., Siddiqui I.A., Thiyagarajan S., Smart B., Meng Q., Zuleger C.L., Mukhtar H., Kenney S.C., et al. MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair. J Invest Dermatol 2013, 133:759-767.
27. Nardiello T., Jungbluth A.A., Mei A., Diliberto M., Huang X., Dabrowski A., Andrade V.C., Wasserstrum R., Ely S., Niesvizky R., et al. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin Cancer Res 2011, 17:4309-4319.
28. Marcar L., Maclaine N.J., Hupp T.R., Meek D.W. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res 2010, 70:10362-10370.
29. Monte M., Simonatto M., Peche L.Y., Bublik D.R., Gobessi S., Pierotti M.A., Rodolfo M., Schneider C. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 2006, 103:11160-11165.
30. Peche L.Y., Scolz M., Ladelfa M.F., Monte M., Schneider C. MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs. Cell Death Differ 2012, 19:926-936.
31. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012, 13:251-262.
32. Hardie D.G. Molecular pathways: is AMPK a friend or a foe in cancer?. Clin Cancer Res 2015.
33. Choi A.M., Ryter S.W., Levine B. Autophagy in human health and disease. N Engl J Med 2013, 368:651-662.
34. Wei Y., Zou Z., Becker N., Anderson M., Sumpter R., Xiao G., Kinch L., Koduru P., Christudass C.S., Veltri R.W., et al. EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell 2013, 154:1269-1284.
35. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012, 12:401-410.
36. Kasznicki J., Sliwinska A., Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med 2014, 2:57.
37. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., Noguchi S., Gnant M., Pritchard K.I., Lebrun F., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
38. Bai S., He B., Wilson E.M. Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol 2005, 25:1238-1257.
39. Bai S., Wilson E.M. Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol 2008, 28:1947-1963.
40. Aprelikova O., Pandolfi S., Tackett S., Ferreira M., Salnikow K., Ward Y., Risinger J.I., Barrett J.C., Niederhuber J. Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res 2009, 69:616-624.
41. Yin B., Zeng Y., Liu G., Wang X., Wang P., Song Y. MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells. Int J Clin Exp Pathol 2014, 7:2934-2941.
42. Yamada R., Takahashi A., Torigoe T., Morita R., Tamura Y., Tsukahara T., Kanaseki T., Kubo T., Watarai K., Kondo T., et al. Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene. Tissue Antigens 2013, 81:428-434.
43. Wienand K., Shires K. The use of MAGE C1 and flow cytometry to determine the malignant cell type in multiple myeloma. PLoS One 2015, 10:e0120734.
44. Atanackovic D., Luetkens T., Hildebrandt Y., Arfsten J., Bartels K., Horn C., Stahl T., Cao Y., Zander A.R., Bokemeyer C., et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res 2009, 15:1343-1352.
45. Andrade V.C., Vettore A.L., Felix R.S., Almeida M.S., Carvalho F., Oliveira J.S., Chauffaille M.L., Andriolo A., Caballero O.L., Zago M.A., et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 2008, 8:2.
46. Weber J., Salgaller M., Samid D., Johnson B., Herlyn M., Lassam N., Treisman J., Rosenberg S.A. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res 1994, 54:1766-1771.
47. De Smet C., Lurquin C., Lethe B., Martelange V., Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999, 19:7327-7335.
48. Schwarzenbach H., Eichelser C., Steinbach B., Tadewaldt J., Pantel K., Lobanenkov V., Loukinov D. Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein. BMC Cancer 2014, 14:796.
49. Wischnewski F., Pantel K., Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006, 4:339-349.
50. Yang B., Wu J., Maddodi N., Ma Y., Setaluri V., Longley B.J. Epigenetic control of MAGE gene expression by the KIT tyrosine kinase. J Invest Dermatol 2007, 127:2123-2128.
51. Kondo T., Zhu X., Asa S.L., Ezzat S. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin Cancer Res 2007, 13:4713-4720.
52. Khwaja A., Rodriguez-Viciana P., Wennstrom S., Warne P.H., Downward J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J 1997, 16:2783-2793.
53. Hadari Y.R., Gotoh N., Kouhara H., Lax I., Schlessinger J. Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci U S A 2001, 98:8578-8583.
54. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 1999, 31:1053-1074.
55. Schlaepfer D.D., Hanks S.K., Hunter T., van der Geer P. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature 1994, 372:786-791.
56. Kouhara H., Hadari Y.R., Spivak-Kroizman T., Schilling J., Bar-Sagi D., Lax I., Schlessinger J. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 1997, 89:693-702.
57. Vatolin S., Abdullaev Z., Pack S.D., Flanagan P.T., Custer M., Loukinov D.I., Pugacheva E., Hong J.A., Morse H., Schrump D.S., et al. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005, 65:7751-7762.
58. De Smet C., Courtois S.J., Faraoni I., Lurquin C., Szikora J.P., De Backer O., Boon T. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics 1995, 42:282-290.
59. Wischnewski F., Friese O., Pantel K., Schwarzenbach H. Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res 2007, 5:749-759.
60. Tyagi P., Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009, 10:371-374.
61. Ruiz R., Hunis B., Raez L.E. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines. Curr Oncol Rep 2014, 16:400.
62. Linette G.P., Stadtmauer E.A., Maus M.V., Rapoport A.P., Levine B.L., Emery L., Litzky L., Bagg A., Carreno B.M., Cimino P.J., et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013, 122:863-871.
63. Morgan R.A., Chinnasamy N., Abate-Daga D., Gros A., Robbins P.F., Zheng Z., Dudley M.E., Feldman S.A., Yang J.C., Sherry R.M., et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013, 36:133-151.
64. Kozakova L., Vondrova L., Stejskal K., Charalabous P., Kolesar P., Lehmann A.R., Uldrijan S., Sanderson C.M., Zdrahal Z., Palecek J.J. The melanoma-associated antigen 1 (MAGEA1) protein stimulates the E3 ubiquitin-ligase activity of TRIM31 within a TRIM31-MAGEA1-NSE4 complex. Cell Cycle 2015, 14:920-930.
65. Marcar L., Ihrig B., Hourihan J., Bray S.E., Quinlan P.R., Jordan L.B., Thompson A.M., Hupp T.R., Meek D.W. MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4. PLoS One 2015, 10:e0127713.
66. Xiao T.Z., Suh Y., Longley B.J. MAGE proteins regulate KRAB zinc finger transcription factors and KAP1 E3 ligase activity. Arch Biochem Biophys 2014, 563:136-144.
67. Rual J.F., Venkatesan K., Hao T., Hirozane-Kishikawa T., Dricot A., Li N., Berriz G.F., Gibbons F.D., Dreze M., Ayivi-Guedehoussou N., et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 2005, 437:1173-1178.
68. Sasaki A., Masuda Y., Iwai K., Ikeda K., Watanabe K. A RING finger protein Praja1 regulates Dlx5-dependent transcription through its ubiquitin ligase activity for the Dlx/Msx-interacting MAGE/Necdin family protein, Dlxin-1. J Biol Chem 2002, 277:22541-22546.
69. Teuber J., Mueller B., Fukabori R., Lang D., Albrecht A., Stork O. The ubiquitin ligase Praja1 reduces NRAGE expression and inhibits neuronal differentiation of PC12 cells. PLoS One 2013, 8:e63067.
70. Kendall S.E., Battelli C., Irwin S., Mitchell J.G., Glackin C.A., Verdi J.M. NRAGE mediates p38 activation and neural progenitor apoptosis via the bone morphogenetic protein signaling cascade. Mol Cell Biol 2005, 25:7711-7724.
71. Jordan B.W., Dinev D., LeMellay V., Troppmair J., Gotz R., Wixler L., Sendtner M., Ludwig S., Rapp U.R. Neurotrophin receptor-interacting mage homologue is an inducible inhibitor of apoptosis protein-interacting protein that augments cell death. J Biol Chem 2001, 276:39985-39989.
72. Mouri A., Sasaki A., Watanabe K., Sogawa C., Kitayama S., Mamiya T., Miyamoto Y., Yamada K., Noda Y., Nabeshima T. MAGE-D1 regulates expression of depression-like behavior through serotonin transporter ubiquitylation. J Neurosci 2012, 32:4562-4580.
73. Taylor E.M., Copsey A.C., Hudson J.J., Vidot S., Lehmann A.R. Identification of the proteins, including MAGEG1, that make up the human SMC5-6 protein complex. Mol Cell Biol 2008, 28:1197-1206.
74. Gur I., Fujiwara K., Hasegawa K., Yoshikawa K. Necdin promotes ubiquitin-dependent degradation of PIAS1 SUMO E3 ligase. PLoS One 2014, 9:e99503.
75. Jungbluth A.A., Chen Y.T., Busam K.J., Coplan K., Kolb D., Iversen K., Williamson B., Van Landeghem F.K., Stockert E., Old L.J. CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 2002, 99:839-845.
76. Curioni-Fontecedro A., Nuber N., Mihic-Probst D., Seifert B., Soldini D., Dummer R., Knuth A., van den Broek M., Moch H. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS One 2011, 6:e21418.
77. Hou S.Y., Sang M.X., Geng C.Z., Liu W.H., Lu W.H., Xu Y.Y., Shan B.E. Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism. Arch Med Res 2014, 45:44-51.
78. Chen Y.T., Ross D.S., Chiu R., Zhou X.K., Chen Y.Y., Lee P., Hoda S.A., Simpson A.J., Old L.J., Caballero O., et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 2011, 6:e17876.
79. Zhang S., Zhou X., Yu H., Yu Y. Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer 2010, 10:163.
80. Li M., Yuan Y.H., Han Y., Liu Y.X., Yan L., Wang Y., Gu J. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res 2005, 11:1809-1814.